Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Affinia Therapeutics has raised $40.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
Affinia Therapeutics's investors include RA Capital Management, Eli Lilly, New Enterprise Associates, Perceptive Advisors, TCG Crossover.
Affinia Therapeutics is headquartered in Waltham, United States.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Affinia Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Affinia Therapeutics — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/affinia-therapeutics. Accessed September 13, 2026.
VCBacked. (2025). Affinia Therapeutics — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/affinia-therapeutics
{{cite web |title=Affinia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/affinia-therapeutics |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated